Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Pharmaceuticals · 11.08.2023 · 16 (8) · 1140
DOI: 10.3390/ph16081140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 11.08.2023. Verfasst von Abraham Hang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Vision Science, Ernest E. Tschannen Eye Institute, University of California Davis Eye Center, 4860 Y Street, Sacramento…. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from University of California Davis, Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from the University of California Davis (SSP).
Abstract (Originalsprache)
Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well as retinal vascular leakage leading to macular edema. As such, VEGF plays an important role in mediating visually significant complications associated with common retinal disorders such as diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. Various drugs that inhibit vascular endothelial growth factors (anti-VEGF therapies) have been developed to minimize vision loss associated with these disorders. These drugs are injected into the vitreous cavity in a clinic setting at regular intervals. This article provides an overview of the various anti-VEGF drugs used in ophthalmology and the common retinal conditions that benefit from this therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology & Vision Science, Ernest E. Tschannen Eye Institute, University of California Davis Eye Center, 4860 Y Street, Sacramento, CA 95817, USA.
- School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
ORCID-Profile: Susanna S Park
Förderung
- Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from University of California Davis
- Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from the University of California Davis (SSP)
Zitieren
APA
Hang, A., Feldman, S., Amin, A. P., Ochoa, J. A. R., & Park, S. S. (2023). Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals, 16(8), 1140. https://doi.org/10.3390/ph16081140
Vancouver
Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals. 2023;16(8):1140. doi:10.3390/ph16081140
BibTeX
@article{Hang2023,
author = {Hang, Abraham and Feldman, Samuel and Amin, Aana P and Ochoa, Jorge A Rivas and Park, Susanna S},
title = {Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {8},
pages = {1140},
doi = {10.3390/ph16081140}
}
EUVIMED